Lipid-based Nanocarriers Loaded with Taxanes for the Management of
Breast Cancer: Promises and Challenges

Nishtha       Chaurawal; Charu       Misra; Kaisar       Raza
Abstract

Breast cancer is the leading cause of deaths worldwide among women. Taxanes (most propitious class of diterpenes) have shown dynamic potentials in the treatment of early and metastatic breast cancer. However, challenges like poor bioavailability, low tissue-permeability, compromised aqueous solubility, and dose-dependent side-effects limit the clinical applications of these drugs. Henceforth, to overcome these challenges, various nanotechnology-based drug delivery systems are being explored for the delivery of taxanes in the management of breast cancer. One such promising nanocarrier category is lipid-based nanocarriers, which employ the meritorious features of a variety of lipids, both of natural and synthetic origin. It is also known that lipid uptake plays a significant role in breast cancer cells proliferation and tumor genesis. However, lipid-based nanocarriers could be a great choice to nanoencapsulate the poorly soluble and permeable taxanes for breast cancer management. These systems have an immense promise of bioavailability enhancement, spatial and temporal taxane delivery, improved efficacy, reduced dosing frequency, and even mild inhibition of the P-gp efflux mechanism. Apart from these promises, these carriers are not yet available for the benefit of the end-user. The present review will not only discuss the merits, progress, and promises of these systems but also ponder upon the various challenges faced by these carriers to reach the clinics for the benefit of the patients afflicted with breast cancer.
Keywords: Bioavailability, sustain release, novel drug delivery systems, drug release cytotoxicity, lipid-based nanocarriers, breast cancer cells.
Graphical Abstract

[1] 
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin  2013; 63(1): 11-30.
[http://dx.doi.org/10.3322/caac.21166] [PMID: 23335087] 
[2] 
Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res  2017; 50(1): 33.
[http://dx.doi.org/10.1186/s40659-017-0140-9] [PMID: 28969709] 
[3] 
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin  2007; 57(1): 43-66.
[http://dx.doi.org/10.3322/canjclin.57.1.43] [PMID: 17237035] 
[4] 
Druesne-Pecollo N, Touvier M, Barrandon E, et al. Excess body weight and second primary cancer risk after breast cancer: A systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat  2012; 135(3): 647-54.
[http://dx.doi.org/10.1007/s10549-012-2187-1] [PMID: 22864804] 
[5] 
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin  2015; 65(2): 87-108.
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787] 
[6] 
Press release N° 2018; 263 Available from: https://wwwiarcwhoint/wp-content/uploads/2018/09/pr263_Epdf 
[7] 
Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: Epidemiology and etiology. Cell Biochem Biophys  2015; 72(2): 333-8.
[http://dx.doi.org/10.1007/s12013-014-0459-6] [PMID: 25543329] 
[8] 
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338] 
[9] 
Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: Variations in epidemiology and survival.Clinical breast cancer.  Elsevier Inc. 2005; pp. 391-401.
[http://dx.doi.org/10.3816/CBC.2005.n.043] 
[10] 
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China.The lancet oncology. Lancet Publishing Group 2014.
[http://dx.doi.org/10.1016/S1470-2045(13)70567-9] 
[11] 
Cooperman AM, Hermann R. Breast cancer: An overview. Surg Clin North Am  1984; 64(6): 1031-8.
[http://dx.doi.org/10.1016/S0039-6109(16)43476-6] [PMID: 6393393] 
[12] 
McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med  2016; 57(Suppl. 1): 9S-16S.
[http://dx.doi.org/10.2967/jnumed.115.157834] [PMID: 26834110] 
[13] 
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med  2002; 347(16): 1233-41.
[http://dx.doi.org/10.1056/NEJMoa022152] [PMID: 12393820] 
[14] 
McLaughlin SA. Surgical management of the breast: Breast conservation therapy and mastectomy. Surg Clin North Am  2013; 93(2): 411-28.
[http://dx.doi.org/10.1016/j.suc.2012.12.006] [PMID: 23464693] 
[15] 
Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet  2011; 378(9804): 1707-16.
[http://dx.doi.org/10.1016/S0140-6736(11)61629-2] [PMID: 22019144] 
[16] 
Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol  2019; 7(1): 3-23.
[http://dx.doi.org/10.2174/2211738507666190122111224] [PMID: 30666921] 
[17] 
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med  2005; 353(16): 1659-72.
[http://dx.doi.org/10.1056/NEJMoa052306] [PMID: 16236737] 
[18] 
de Matteis A, Nuzzo F, D’Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: A single-center, phase II study. Cancer  2002; 94(4): 895-901.
[http://dx.doi.org/10.1002/cncr.20335] [PMID: 11920456] 
[19] 
Baselga J, Coleman R E, Cortés J, Janni W. Advances in the management of HER2-positive early breast cancer.Critical reviews in oncology/hematology.  Elsevier Ireland Ltd 2017; pp. 113-22.
[http://dx.doi.org/10.1016/j.critrevonc.2017.10.001] 
[20] 
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med  2005; 353(16): 1673-84.
[http://dx.doi.org/10.1056/NEJMoa052122] [PMID: 16236738] 
[21] 
Berrada N, Delaloge S, André F. Treatment of triple-negative metastatic breast cancer: Toward individualized targeted treatments or chemosensitization?  Ann Oncol  2010; 21(Suppl 7): vii30-5.
[http://dx.doi.org/10.1093/annonc/mdq279] 
[22] 
Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol  2020; 84(April): 106535.
[http://dx.doi.org/10.1016/j.intimp.2020.106535] [PMID: 32361569] 
[23] 
Quinn MJ, Allen E. UK association of cancer registries changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. BMJ  1995; 311(7017): 1391-5.
[24] 
Joerger M, Thürlimann B. Chemotherapy regimens in early breast cancer: Major controversies and future outlook. Expert Rev Anticancer Ther  2013; 13(2): 165-78.
[http://dx.doi.org/10.1586/era.12.172] [PMID: 23406558] 
[25] 
Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer - PubMed.  Available from: https://pubmed.ncbi.nlm.nih.gov/10403473/ [Accessed Jan 29, 2021]
[26] 
Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol  2006; 24(36): 5664-71.
[http://dx.doi.org/10.1200/JCO.2006.07.3916] [PMID: 17116941] 
[27] 
Tang SC. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer. Cancer Invest  2009; 27(2): 206-14.
[http://dx.doi.org/10.1080/07357900802178520] [PMID: 19235594] 
[28] 
Ahmed S E, Martins A M, Husseini G A. The use of ultrasound to release chemotherapeutic drugs from micelles and liposomes.Journal of drug targeting.  Informa healthcare 2015; pp. 16-42.
[http://dx.doi.org/10.3109/1061186X.2014.954119] 
[29] 
Azarmi S, Tao X, Chen H, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm  2006; 319(1-2): 155-61.
[http://dx.doi.org/10.1016/j.ijpharm.2006.03.052] [PMID: 16713150] 
[30] 
Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come. Pharmacol Rev  2016; 68(3): 701-87.
[http://dx.doi.org/10.1124/pr.115.012070] [PMID: 27363439] 
[31] 
Libson S, Lippman M. A review of clinical aspects of breast cancer. Int Rev Psychiatry  2014; 26(1): 4-15.
[http://dx.doi.org/10.3109/09540261.2013.852971] [PMID: 24716497] 
[32] 
Fahy E, Cotter D, Sud M, Subramaniam S. Lipid classification, structures and tools. Biochim Biophys Acta  2011; 1811(11): 637-47.
[http://dx.doi.org/10.1016/j.bbalip.2011.06.009] [PMID: 21704189] 
[33] 
Bezaire V, Mairal A, Ribet C, et al. Contribution of adipose triglyceride lipase and hormone-sensitive lipase to lipolysis in hMADS adipocytes. J Biol Chem  2009; 284(27): 18282-91.
[http://dx.doi.org/10.1074/jbc.M109.008631] [PMID: 19433586] 
[34] 
Ahmadian M, Abbott MJ, Tang T, et al. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab  2011; 13(6): 739-48.
[http://dx.doi.org/10.1016/j.cmet.2011.05.002] [PMID: 21641555] 
[35] 
Zechner R, Zimmermann R, Eichmann TO, et al. FAT SIGNALS-lipases and lipolysis in lipid metabolism and signaling. Cell Metab  2012; 15(3): 279-91.
[http://dx.doi.org/10.1016/j.cmet.2011.12.018] [PMID: 22405066] 
[36] 
Rahman MA, Harwansh R, Mirza MA, Hussain S, Hussain A. Oral lipid based drug delivery system (LBDDS): Formulation, characterization and application: A review. Curr Drug Deliv  2011; 8(4): 330-45.
[http://dx.doi.org/10.2174/156720111795767906] [PMID: 21453264] 
[37] 
Schulman JH, Stoeckenius W, Prince LM. Mechanism of formation and structure of micro emulsions by electron microscopy. J Phys Chem  1959; 63(10): 1677-80.
[http://dx.doi.org/10.1021/j150580a027] 
[38] 
Tartaro G, Mateos H, Schirone D, Angelico R, Palazzo G. Microemulsion microstructure(s): A tutorial review. Nanomaterials (Basel)  2020; 10(9): 1-40.
[http://dx.doi.org/10.3390/nano10091657] [PMID: 32846957] 
[39] 
Mason TG, Wilking JN, Meleson K, Chang CB, Graves SM. Nanoemulsions: Formation, structure, and physical properties. J Phys Condens Matter  2006; 18(41): R635.
[http://dx.doi.org/10.1088/0953-8984/18/41/R01] 
[40] 
Aboofazeli R. Nanometric-scaled emulsions (nanoemulsions).Iranian journal of pharmaceutical research.  IJPR 2010; 9(4): 325-6.
[http://dx.doi.org/10.22037/ijpr.2010.897] 
[41] 
Singh Y, Meher JG, Raval K, et al. Nanoemulsion: Concepts, development and applications in drug delivery. J Control Release  2017; 252: 28-49.
[http://dx.doi.org/10.1016/j.jconrel.2017.03.008] [PMID: 28279798] 
[42] 
Dokania S, Joshi AK. Self-microemulsifying drug delivery system (SMEDDS)-challenges and road ahead. Drug Deliv  2015; 22(6): 675-90.
[http://dx.doi.org/10.3109/10717544.2014.896058] [PMID: 24670091] 
[43] 
Akula S, Gurram AK, Devireddy SR. Self-microemulsifying drug delivery systems: An attractive strategy for enhanced therapeutic profile. Int Sch Res Notices  2014; 2014: 964051.
[http://dx.doi.org/10.1155/2014/964051] [PMID: 27382619] 
[44] 
Singh B, Bandopadhyay S, Kapil R, Singh R, Katare OP. Self-emulsifying drug delivery systems (SEDDS): Formulation development, characterization, and applications.Critical reviews in therapeutic drug carrier systems.  Begell House Inc. 2009; pp. 427-521.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i5.10] 
[45] 
Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm  2007; 66(2): 227-43.
[http://dx.doi.org/10.1016/j.ejpb.2006.10.014] [PMID: 17127045] 
[46] 
Rahman M, Beg S, Verma A, Anwar F, Samad A, Kumar V. Liposomal-based therapeutic carriers for vaccine and gene delivery. In: Nanotechnology-based approaches for targeting and delivery of drugs and genes.  Elsevier Inc. 2017; pp. 151-66.
[http://dx.doi.org/10.1016/B978-0-12-809717-5.00005-1] 
[47] 
Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. Adv Pharm Bull  2017; 7(1): 3-9.
[http://dx.doi.org/10.15171/apb.2017.002] [PMID: 28507932] 
[48] 
T. Florence A. Pharmaceutical nanotechnology: A new journal for an evolving science. Pharm Nanotechnol  2012; 1(1): 2-3.
[http://dx.doi.org/10.2174/2211738511301010002] 
[49] 
Chen S, Hanning S, Falconer J, Locke M, Wen J. Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm  2019; 144(August): 18-39.
[http://dx.doi.org/10.1016/j.ejpb.2019.08.015] [PMID: 31446046] 
[50] 
Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release  2000; 65(3): 403-18.
[http://dx.doi.org/10.1016/S0168-3659(99)00222-9] [PMID: 10699298] 
[51] 
Zahid SR, Upmanyu N, Dangi S, Ray SK, Jain P, Parkhe G. A novel vesicular carrier for transdermal drug delivery. J Drug Deliv Ther  2018; 8(6): 318-26.
[52] 
Mishra V, Bansal KK, Verma A, et al. Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics  2018; 10(4): 1-21.
[http://dx.doi.org/10.3390/pharmaceutics10040191] [PMID: 30340327] 
[53] 
Tekade RK, Maheshwari R, Tekade M, Chougule MB. Solid lipid nanoparticles for targeting and delivery of drugs and genes. In: Nanotechnology-based approaches for targeting and delivery of drugs and genes.  Elsevier Inc. 2017; pp. 256-86.
[http://dx.doi.org/10.1016/B978-0-12-809717-5.00010-5] 
[54] 
Mukherjee S, Ray S, Thakur R S. Solid lipid nanoparticles: A modern formulation approach in drug delivery system.Indian journal of pharmaceutical sciences.  Wolters Kluwer - Medknow Publications 2009; pp. 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] 
[55] 
Beloqui A, Solinís M Á, Rodríguez-Gascón A, Almeida A J, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics.Nanomedicine: Nanotechnology, biology, and medicine.  Elsevier Inc. 2016; pp. 143-61.
[http://dx.doi.org/10.1016/j.nano.2015.09.004] 
[56] 
Olbrich C, Gessner A, Kayser O, Müller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target  2002; 10(5): 387-96.
[http://dx.doi.org/10.1080/1061186021000001832] [PMID: 12442809] 
[57] 
Nasr M, Mansour S, Mortada ND, El Shamy AA. Lipospheres as carriers for topical delivery of aceclofenac: Preparation, characterization and in vivo evaluation. AAPS PharmSciTech  2008; 9(1): 154-62.
[http://dx.doi.org/10.1208/s12249-007-9028-2] [PMID: 18446476] 
[58] 
Lipid nanoparticles (SLN and NLC) for drug delivery | Request PDF.  Available from: https://www.researchgate.net/publication/284595258_Lipid_nanoparticles_SLN_and_NLC_for_drug_delivery [Accessed Jan 29, 2021]
[59] 
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev  2002; 54(Suppl 1): S131-55.
[http://dx.doi.org/10.1016/S0169-409X(02)00118-7] 
[60] 
Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere®): A review of preclinical and clinical experience. Part I: Preclinical experience.Anti-cancer drugs.  Lippincott Williams and Wilkins 1995; pp. 339-55.
[http://dx.doi.org/10.1097/00001813-199506000-00001] 
[61] 
Jain V, Kumar H, Anod HV, et al. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. J Control Release  2020; 326(April): 628-47.
[http://dx.doi.org/10.1016/j.jconrel.2020.07.003] [PMID: 32653502] 
[62] 
Drugs approved for head and neck cancer - national cancer institute.  Available from: https://www.cancer.gov/about-cancer/treatment/drugs/head-neck [Accessed Jan 29, 2021]
[63] 
Feng L, Mumper R J. A critical review of lipid-based nanoparticles for taxane delivery.Cancer letters.  Elsevier Ireland Ltd 2013; pp. 157-75.
[http://dx.doi.org/10.1016/j.canlet.2012.07.006] 
[64] 
Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res  2011; 71(18): 6019-29.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-1417] [PMID: 21799031] 
[65] 
Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: A patent perspective. Expert Opin Ther Pat  2016; 26(1): 1-20.
[http://dx.doi.org/10.1517/13543776.2016.1111872] [PMID: 26651178] 
[66] 
Zhang JQ, Zhang ZR, Yang H, Tan QY, Qin SR, Qiu XL. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies. Pharm Res  2005; 22(4): 573-83.
[http://dx.doi.org/10.1007/s11095-005-2496-8] [PMID: 15846465] 
[67] 
Yang T, Choi MK, Cui FD, et al. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res  2007; 24(12): 2402-11.
[http://dx.doi.org/10.1007/s11095-007-9425-y] [PMID: 17828616] 
[68] 
Saraf S, Jain A, Tiwari A, Verma A, Panda P K, Jain S K. Advances in liposomal drug delivery to cancer: An overview.Journal of drug delivery science and technology.  Editions de Sante 2020; p. 101549.
[http://dx.doi.org/10.1016/j.jddst.2020.101549] 
[69] 
Monteiro LOF, Fernandes RS, Castro L, et al. Paclitaxel-Loaded folate-coated pH-sensitive liposomes enhance cellular uptake and antitumor activity. Mol Pharm  2019; 16(8): 3477-88.
[http://dx.doi.org/10.1021/acs.molpharmaceut.9b00329] [PMID: 31257891] 
[70] 
Koudelka S, Turánek J. Liposomal paclitaxel formulations. J Control Release  2012; 163(3): 322-34.
[http://dx.doi.org/10.1016/j.jconrel.2012.09.006] [PMID: 22989535] 
[71] 
Jiang L, He B, Pan D, et al. Anti-cancer efficacy of paclitaxel loaded in pH triggered liposomes. J Biomed Nanotechnol  2016; 12(1): 79-90.
[http://dx.doi.org/10.1166/jbn.2016.2123] [PMID: 27301174] 
[72] 
Eloy JO, Petrilli R, Topan JF, et al. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces  2016; 141: 74-82.
[http://dx.doi.org/10.1016/j.colsurfb.2016.01.032] [PMID: 26836480] 
[73] 
Han B, Yang Y, Chen J, et al. Preparation, characterization, and pharmacokinetic study of a novel long-acting targeted paclitaxel liposome with antitumor activity. Int J Nanomedicine  2020; 15: 553-71.
[http://dx.doi.org/10.2147/IJN.S228715] [PMID: 32158208] 
[74] 
Kamal MM, Nazzal S. Novel sulforaphane-enabled self-microemulsifying delivery systems (SFN-SMEDDS) of taxanes: Formulation development and in vitro cytotoxicity against breast cancer cells. Int J Pharm  2018; 536(1): 187-98.
[http://dx.doi.org/10.1016/j.ijpharm.2017.11.063] [PMID: 29195916] 
[75] 
Kang BK, Chon SK, Kim SH, et al. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int J Pharm  2004; 286(1-2): 147-56.
[http://dx.doi.org/10.1016/j.ijpharm.2004.08.008] [PMID: 15501011] 
[76] 
Yu K, Zhou Y, Li Y, et al. Comparison of three different conjugation strategies in the construction of herceptin-bearing paclitaxel-loaded nanoparticles. Biomater Sci  2016; 4(8): 1219-32.
[http://dx.doi.org/10.1039/C6BM00308G] [PMID: 27367271] 
[77] 
Campos J, Varas-Godoy M, Haidar ZS. Physicochemical characterization of chitosan-hyaluronan-coated solid lipid nanoparticles for the targeted delivery of paclitaxel: A proof-of-concept study in breast cancer cells. Nanomedicine (Lond)  2017; 12(5): 473-90.
[http://dx.doi.org/10.2217/nnm-2016-0371] [PMID: 28181464] 
[78] 
Li S, Su Z, Sun M, et al. An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery. Int J Pharm  2012; 436(1-2): 248-57.
[http://dx.doi.org/10.1016/j.ijpharm.2012.06.040] [PMID: 22732672] 
[79] 
Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials  2007; 28(12): 2137-46.
[http://dx.doi.org/10.1016/j.biomaterials.2007.01.014] [PMID: 17257668] 
[80] 
Baek JS, Kim JH, Park JS, Cho CW. Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection. Int J Nanomedicine  2015; 10: 5397-405.
[http://dx.doi.org/10.2147/IJN.S86474] [PMID: 26347363] 
[81] 
Gu Z, Chang M, Fan Y, Shi Y, Lin G. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel. Colloids Surf B Biointerfaces  2017; 160: 395-405.
[http://dx.doi.org/10.1016/j.colsurfb.2017.09.052] [PMID: 28965079] 
[82] 
Odeh F, Naffa R, Azzam H, et al. Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel. Heliyon  2019; 5(11): e02919.
[http://dx.doi.org/10.1016/j.heliyon.2019.e02919] [PMID: 31844767] 
[83] 
Rodallec A, Brunel JM, Giacometti S, et al. Docetaxel-trastuzumab stealth immunoliposome: Development and in vitro proof of concept studies in breast cancer. Int J Nanomedicine  2018; 13: 3451-65.
[http://dx.doi.org/10.2147/IJN.S162454] [PMID: 29950829] 
[84] 
Zhang H, Gong W, Wang ZY, et al. Preparation, characterization, and pharmacodynamics of thermosensitive liposomes containing docetaxel. J Pharm Sci  2014; 103(7): 2177-83.
[http://dx.doi.org/10.1002/jps.24019] [PMID: 24846075] 
[85] 
Liu H, Tu L, Zhou Y, et al. Improved bioavailability and antitumor effect of docetaxel by TPGS modified proniosomes: In vitro and in vivo Evaluations. Sci Rep  2017; 7: 43372.
[http://dx.doi.org/10.1038/srep43372] [PMID: 28266539] 
[86] 
Afzal SM, Shareef MZ, Dinesh T, Kishan V. Folate-PEG-decorated docetaxel lipid nanoemulsion for improved antitumor activity. Nanomedicine (Lond)  2016; 11(16): 2171-84.
[http://dx.doi.org/10.2217/nnm-2016-0120] [PMID: 27463694] 
[87] 
Yadav S, Gupta S. Development and in vitro characterization of docetaxel-loaded ligand appended solid fat nanoemulsions for potential use in breast cancer therapy. Artif Cells Nanomed Biotechnol  2015; 43(2): 93-102.
[http://dx.doi.org/10.3109/21691401.2013.845569] [PMID: 24195582] 
[88] 
Verma P, Meher JG, Asthana S, Pawar VK, Chaurasia M, Chourasia MK. Perspectives of nanoemulsion assisted oral delivery of docetaxel for improved chemotherapy of cancer. Drug Deliv  2016; 23(2): 479-88.
[http://dx.doi.org/10.3109/10717544.2014.920430] [PMID: 24901205] 
[89] 
Wang M, You SK, Lee HK, et al. Development and evaluation of docetaxel-phospholipid complex loaded self-microemulsifying drug delivery system: Optimization and in vitro/ex vivo studies. Pharmaceutics  2020; 12(6): 1-19.
[http://dx.doi.org/10.3390/pharmaceutics12060544] [PMID: 32545452] 
[90] 
Kommineni N, Mahira S, Domb AJ, Khan W. Cabazitaxel-loaded nanocarriers for cancer therapy with reduced side effects. Pharmaceutics  2019; 11(3): 1-22.
[http://dx.doi.org/10.3390/pharmaceutics11030141] [PMID: 30934535] 
Cite As
Current Drug Targets

Lipid-based Nanocarriers Loaded with Taxanes for the Management of Breast Cancer: Promises and Challenges

Abstract

Graphical Abstract
